Exelixis, Inc. (EXEL)
EXELNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$71.74
0.0000 (0.00%) today
At the close, Nov 9, 4:00 PM ET. Pre-market $71.82 +0.11%
- Market cap
- $17.52bn
- P/E
- 21.5
- EPS, last 4 quarters
- $3.34
- Dividend yield
- –
- Day range
- –
- 52-week range
- $39.71 to $73.69
- Average volume
- 2.44m
- Previous close
- $71.74
Analysts
12 coveringHold4 buy, 7 hold, 1 sell
Targets a year out average $60.09, -16.2% from here
Earnings
next estimate $0.9700Next report
Dec 2025
+29.4%
Mar 2026
+17.9%
Jun 2026
+9.3%
Sep 2026
+7.6%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $598.66m | $610.81m | $628.69m | $658.70m |
| Gross profit | $572.18m | $590.86m | $608.03m | $632.46m |
| Operating income | $235.22m | $251.34m | $248.41m | $268.42m |
| Net income | $244.53m | $210.47m | $212.05m | $218.09m |
Last four quarters: revenue $2.50bn, margin 35.5%, free cash flow $1.16bn
News
8 latest- Here's Why Exelixis (EXEL) is a Strong Growth StockZacks · 22 hours ago
- The Top 5 Biotech Stocks I'd Buy Right Now Without Any HesitationThe Motley Fool · 1 day ago
- Exelixis (EXEL) International Revenue in Focus: Trends and ExpectationsZacks · Nov 2, 2026
- EXEL Q3 Earnings Beat Estimates on Strong Cabometyx SalesZacks · Oct 30, 2026
- Exelixis (EXEL) Q3 2026 Earnings Call TranscriptThe Motley Fool · Oct 30, 2026
- Exelixis, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate UpdatesFintel · Oct 30, 2026
- What Exelixis (EXEL) Said on Its Q3 Earnings CallMarketBeat · Oct 29, 2026
- Exelixis (EXEL) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks · Oct 29, 2026
The company
Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules and biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our pipeline of franchise molecules, including our novel oral kinase inhibitor zanzalintinib, and to extend the impact of our flagship commercial product, CABOMETYX (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- exelixis.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.